Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NICO - CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer

NCT03721757 is registered in ClinicalTrials.gov with The Clatterbridge Cancer Centre NHS Foundation Trust as lead sponsor.

NCT NCT03721757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03721757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NICO - CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer
Lead sponsor
The Clatterbridge Cancer Centre NHS Foundation Trust
Phase
Phase 2
Overall status
Completed
Start date
May 10, 2019
Completion date
February 24, 2025
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the oral cavity